Prostate Cancer - Results from #480

Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial. August 1, 2024

Brachytherapy based microboosting to the dominant intraprostatic lesion in prostate cancer: A systematic review on treatment outcomes and toxicities. August 1, 2024

Cancer centers of excellence for the multidisciplinary management of urologic cancers The intersection between education, research, and healthcare. August 1, 2024

Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer. August 1, 2024

Comparison of data fusion strategies for automated prostate lesion detection using mpMRI correlated with whole mount histology. August 1, 2024

Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value. August 1, 2024

Patient Perceptions of Standardized Risk Language Used in ACR Prostate MRI PI-RADS Scores July 31, 2024

Combining PSMA-PET and PROMISE to Re-Define Disease Stage and Risk in Patients with Prostate Cancer: A Multicentre Retrospective Study July 31, 2024

CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation. July 31, 2024

Prostate cancer detection through unbiased capture of methylated cell-free DNA. July 31, 2024

USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity. July 31, 2024

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review. July 31, 2024

Readability Assessment of Patient Education Materials on Uro-oncological Diseases Using Automated Measures. July 31, 2024

Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. July 31, 2024

Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer. July 31, 2024

Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE). July 31, 2024

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase 2 Trial. July 31, 2024

Briganti's 2012 nomogram is an independent predictor of prostate cancer progression in EAU intermediate-risk class: results from 527 patients treated with robotic surgery. July 31, 2024

Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. July 30, 2024

Organ-confined pT2 ISUP4/5 vs. nonorgan confined pT3/4 ISUP2 vs. ISUP3 prostate cancer: Differences in biochemical recurrence-free survival after radical prostatectomy. July 30, 2024

Page 25 of 1436